Cover Image
Market Research Report

Hemostasis Rapid Tests & Point of Care (POC) - Medical Devices Pipeline Assessment, 2019

Published by GlobalData Product code 916558
Published Content info 31 Pages
Delivery time: 1-2 business days
Price
Back to Top
Hemostasis Rapid Tests & Point of Care (POC) - Medical Devices Pipeline Assessment, 2019
Published: November 1, 2019 Content info: 31 Pages
Description

GlobalData's Medical Devices sector report, "Hemostasis Rapid Tests & Point of Care (POC) - Medical Devices Pipeline Assessment, 2019" provides an overview of Hemostasis Rapid Tests & Point of Care (POC) currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Hemostasis Rapid Tests & Point of Care (POC) pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Hemostasis Rapid Tests & Point of Care (POC) under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Hemostasis Rapid Tests & Point of Care (POC) and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Hemostasis Rapid Tests & Point of Care (POC) under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date
Table of Contents
Product Code: GDME0804EPD

Table of Contents

1 Table of Contents

  • 1.1 List of Tables 3
  • 1.2 List of Figures 4

2 Introduction 5

  • 2.1 Hemostasis Rapid Tests & Point of Care (POC) Overview 5

3 Products under Development 6

  • 3.1 Hemostasis Rapid Tests & Point of Care (POC) Pipeline Products by Stage of Development 6
  • 3.2 Hemostasis Rapid Tests & Point of Care (POC) Pipeline Products by Territory 7
  • 3.3 Hemostasis Rapid Tests & Point of Care (POC) Pipeline Products by Regulatory Path 8
  • 3.4 Hemostasis Rapid Tests & Point of Care (POC) Pipeline Products by Estimated Approval Date 9

4 Hemostasis Rapid Tests & Point of Care (POC) Pipeline Products under Development by Companies 10

  • 4.1 Hemostasis Rapid Tests & Point of Care (POC) Companies - Pipeline Products by Stage of Development 10
  • 4.2 Hemostasis Rapid Tests & Point of Care (POC) Pipeline Products by Stage of Development 11

5 Hemostasis Rapid Tests & Point of Care (POC) Companies and Product Overview 12

  • 5.1 Atomo Diagnostics Pty Ltd Company Overview 12
    • 5.1.1 Atomo Diagnostics Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview 12
  • 5.2 Carclo Diagnostic Solutions Ltd Company Overview 13
    • 5.2.1 Carclo Diagnostic Solutions Ltd Pipeline Products & Ongoing Clinical Trials Overview 13
  • 5.3 Cascade Metrix LLC Company Overview 14
    • 5.3.1 Cascade Metrix LLC Pipeline Products & Ongoing Clinical Trials Overview 14
  • 5.4 Edan Instruments Inc Company Overview 15
    • 5.4.1 Edan Instruments Inc Pipeline Products & Ongoing Clinical Trials Overview 15
  • 5.5 EKF Diagnostics Holdings Plc Company Overview 16
    • 5.5.1 EKF Diagnostics Holdings Plc Pipeline Products & Ongoing Clinical Trials Overview 16
  • 5.6 Emosis SAS Company Overview 17
    • 5.6.1 Emosis SAS Pipeline Products & Ongoing Clinical Trials Overview 17
  • 5.7 Fraunhofer Institute for Cell Therapy and Immunology Company Overview 18
    • 5.7.1 Fraunhofer Institute for Cell Therapy and Immunology Pipeline Products & Ongoing Clinical Trials Overview 18
  • 5.8 Helena Laboratories Corp Company Overview 19
    • 5.8.1 Helena Laboratories Corp Pipeline Products & Ongoing Clinical Trials Overview 19
  • 5.9 Universal Biosensors Inc Company Overview 26
    • 5.9.1 Universal Biosensors Inc Pipeline Products & Ongoing Clinical Trials Overview 26

6 Hemostasis Rapid Tests & Point of Care (POC) - Recent Developments 27

  • 6.1 Apr 08, 2019: Aggredyne receives FDA clearance for ADP platelet aggregation testing cartridge 27
  • 6.2 Nov 22, 2018: EMOSIS reinforces its Intellectual Property and scientific expertise 27

7 Appendix 28

  • 7.1 Methodology 28
  • 7.2 About GlobalData 31
  • 7.3 Contact Us 31
  • 7.4 Disclaimer 31

List of Tables

  • Table 1: Hemostasis Rapid Tests & Point of Care (POC) Pipeline Products by Stage of Development 6
  • Table 2: Hemostasis Rapid Tests & Point of Care (POC) Pipeline Products by Territory 7
  • Table 3: Hemostasis Rapid Tests & Point of Care (POC) P

List of Figures

  • Figure 1: Hemostasis Rapid Tests & Point of Care (POC) Pipeline Products by Stage of Development 6
  • Figure 2: Hemostasis Rapid Tests & Point of Care (POC) Pipeline Products by Territory 7
  • Figure 3: Hemostasis Rapid Tests & Point of Care (PO
Back to Top